Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal
October 31, 2023 at 07:25 AM EDT
Company plans to seek label expansion for Duchenne muscular dystrophy treatment
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |